Prescribe Acthar Gel now
Start the referral process for your appropriate patients
Tumlin J, Galphin C, Santos R, Rovin B—Kidney International Reports, 2017
To evaluate the impact of Acthar Gel on proteinuria reduction in a patient population with treatment-resistant FSGS
Patient characteristics
Patients had a mean age of >55 years, and more than 90% had received previous treatment with steroids.
Cr=creatinine; eGFR=estimated glomerular filtration rate; NS=nephrotic syndrome; UPCR=urine protein/creatinine ratio.
*Other than steroids, listed therapies are not approved for the reduction of proteinuria in NS.
Assessment after 6 months of Acthar Gel monotherapy
*Complete remission: urine protein to creatinine ratio (UP/CR) <300 mg/g. Partial remission: 50% reduction in UP/CR to <3500 mg/g.
Of the 22 total patients in the study:
One patient required a reduction in the Acthar Gel dose, but no patient discontinued Acthar Gel.
Start the referral process for your appropriate patients
See additional dosing information from clinical experience with Acthar Gel
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References: